@article{5583abec034f48f8aafa83472935c4db,
title = "Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury",
abstract = "Carbon monoxide (CO), one of the products of heme oxygenase action on heme, prevents arteriosclerotic lesions that occur following aorta transplantation; pre-exposure to 250 parts per million of CO for 1 hour before injury suppresses stenosis after carotid balloon injury in rats as well as in mice. The protective effect of CO is associated with a profound inhibition of graft leukocyte infiltration/activation as well as with inhibition of smooth muscle cell proliferation. The antiproliferative effect of CO in vitro requires the activation of guanylate cyclase, the generation of cGMP, the activation of p38 mitogen-activated protein kinases and the expression of the cell cycle inhibitor p21cip1. These findings demonstrate a protective role for CO in vascular injury and support its use as a therapeutic agent.",
author = "Otterbein, {Leo E.} and Zuckerbraun, {Brian S.} and Manabu Haga and Fang Liu and Ruiping Song and Anny Usheva and Christina Stachulak and Natalya Bodyak and {Neal Smith}, R. and Eva Csizmadia and Shivraj Tyagi and Yorihiro Akamatsu and Flavell, {Richard J.} and Billiar, {Timothy R.} and Edith Tzeng and Bach, {Fritz H.} and Choi, {Augustine M.K.} and Soares, {Miguel P.}",
note = "Funding Information: Acknowledgments This work was supported by a grant from the Roche Organ Transplantation Research Foundation (ROTRF; 998521355) awarded to M.P.S.; an Atorvastatin Research Award (AHA) sponsored by Pfizer awarded to M.P.S.; NIH grants HL67040 (M.P.S.), HL58688 (F.H.B.), HL53458 (A.U.), HL60234 (A.M.K.C.), HL5785405 (E.T.); American Heart Association grants 9740246N (A.M.K.C.) and 0160332U (L.E.O.); an AHA sponsored by Pfizer and awarded to L.E.O.; and an Ethicon-Society of University Surgeons Resident Research Award (awarded to B.S.Z.). M.H. was partially supported by a fellowship grant awarded by the Japan Science and Technology Corporation (JST). F.H.B. is the Lewis Thomas Professor at the Harvard Medical School and is a paid consultant for Novartis Pharma.",
year = "2003",
month = feb,
day = "1",
doi = "10.1038/nm817",
language = "English",
volume = "9",
pages = "183--190",
journal = "Nature Medicine",
issn = "1078-8956",
number = "2",
}